Blood cancers

Blood cancer patients show poor responses to mRNA vaccine, especially with anti-CD-20 mAbs

Most people with cancer develop a good immune response after two doses of COVID-19 mRNA (Pfizer, Modena) vaccine, but those with a haematological cancer tend to be non-responders, an international study suggests. An analysis of responses to SARS-CoV-2 mRNA vaccines in 131 cancer patients, treated at two cancer centres in the US and Switzerland found ...

Already a member?

Login to keep reading.

© 2021 the limbic